Americans who were prescribed diet drugs for weight loss are beginning to tell stories about how these drugs may be tied to serious digestive issues they now face. 

The Trends Journal has reported extensively on the recent emergence of weight-loss super drugs that help keep hunger suppressed in patients. These drugs are seen by promoters as a potential quick fix to obesity and a potential boon to the pharmaceutical industry that is in a Fat Race. (See “OPERATION WARP SPEED: OBESITY ADDITION” 27 Jun 2023, “JENNY CRAIG TO CLOSE ITS DOORS, CAN’T COMPETE WITH NEW WEIGHT-LOSS DRUGS” 9 May 2023, and “WEIGHT-LOSS SURGERY FOR CHILDREN IN U.S. JUMPS…WHO CARES ABOUT DIET?” 25 Apr 2023.)

We’ve also reported on the emerging risks possibly tied to taking these drugs. (See “ARE WEIGHT LOSS DRUGS SUICIDE PILLS?” 18 Jul 2023.)

Another side-effect of drugs like Ozempic and Wegovy could be gastroparesis, which is a chronic gastrointestinal disorder. Gastroparesis causes an individual’s stomach muscles to slow to a crawl and prevents the stomach from emptying properly.

CNN interviewed people who were prescribed these drugs who said their health has taken a turn for the worse. 

“I’ve almost been off Ozempic for a year, but I’m still not back to my normal,” Emily Wright, 38, a teacher in Toronto, told the network. 

She has been diagnosed with gastroparesis and cyclic vomiting syndrome, which causes her to throw up multiple times a day. She was then given two more medications to help with her nausea.

Wright told the network that she lost 80 pounds in one year on the drug. 

Novo Nordisk, the creator of these drugs, which contain semaglutide, defended their safety and told CNN that they have been used for 15 years to treat diabetes and “they have been extensively studied in the real world and in clinical trials.”

Dr. Michael Camilleri, a gastroenterologist at the Mayo Clinic, said of the people who shared their cases with CNN they “may just be really unlucky.”

He theorized that some patients may have “borderline slow gastric emptying and starting one of the GLP-1 agonists may precipitate a full-blown gastroparesis.” 

GLP-1 is a hormone produced by the body that is mimicked by these drugs to help people feel fuller longer.  

TRENDPOST: Obesity has impacted the health of millions of Americans and the issue just continues to get worse. 

And as with the coronavirus which was most deadly to those suffering from Type 2 diabetes and obesity, rather than prescribing natural healing to lose weight—exercising, eating healthy etc., governments and the mainstream media only sold getting the vax.  

(See “CANCER RATES SOARING AMONG THE YOUNG, OBESITY IS THE 800-POUND GORILLA IN THE ROOM” 11 Jul 2023, “OBESITY PERMANENTLY REWIRES THE BRAIN TO THWART WEIGHT LOSS” 20 Jun 2023, “BLIMPITIS: AMERICANS ARE STRESSED OUT AND GETTING FATTER” 11 Jul 2023, and “AS FORECAST, COVID LOCKDOWNS LEFT KIDS FAT AND DUMB” 27 Jun 2023.)

Health officials are still trying to determine the health risks that patients who opt for medical intervention face when trying to lose weight.

Dr. Ninh T. Nguyen, a UCI Health bariatric surgeon and past president of the American Society for Metabolic and Bariatric Surgery, said more data is needed to determine whether Ozempic induces gastroparesis or exacerbates an existing underlying condition.

He reminded patients of the fen-phen craze in the 1990s that was called a “miracle” diet drug only to be pulled from shelves in 1997 after cardiovascular complications and heart valve abnormalities emerged in some patients.

“I understand the initial enthusiasm for these new drugs because of their high efficacy for weight loss,” he said, according to a statement. “But this is a chance for us to take a pause and institute further studies to determine if Ozempic and similar medications have a higher risk for gastroparesis.”